Respiratory Therapies: Moving Beyond Symptomatic Relief
This article was originally published in Start Up
Executive Summary
Existing treatments for airway and lung disorders, including allergies, asthma and chronic obstructive pulmonary disease, provide widely effective symptom relief. New products in development aim to halt progression and even reverse the disorders. We profile three emerging respiratory drug developers in this issue: Pearl Therapeutics, Protectimmun and Pulmatrix.
You may also be interested in...
Respira Therapeutics Inc.
Respira Therapeutics Inc.'s method for delivering drugs to the lung is unusual because it does not utilize any chemical and doesn't require special formulations. Instead, a drug-coated bead about the size of a pea sits dead center in a cartridge the size and shape of a lipstick tube. When a person inhales from the device, the bead oscillates and the therapeutic is detached as the patient breathes in.
Start-Up Previews
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.
Pearl Therapeutics Inc.
Drawing on a proprietary porous particle technology to create stable inhalable suspensions, Pearl Therapeutics Inc. has developed a metered-dose inhaler format able to deliver combination products across therapeutics and product types. The company's lead chronic obstructive pulmonary disease MDI candidate combines a long-acting muscarinic antagonist plus a long acting beta-2 agonist. A mid-stage clinical trial demonstrated significant benefits versus blockbuster, market-leading active comparators in patients with moderate-to-very severe COPD.